GILD
Gilead Sciences, Inc.
- Operating cash flow, 2025
- $10.0B
- YoY, 2025
- −7.5%
- 5-year CAGR
- +4.2%
- 10-year CAGR
- −7.2%
Operating cash flow
Operating cash flow by fiscal year
| Period | Operating cash flow | YoY |
|---|---|---|
| 2025 | $10.0B | −7.5% |
| 2024 | $10.8B | +35.2% |
| 2023 | $8.0B | −11.8% |
| 2022 | $9.1B | −20.3% |
| 2021 | $11.4B | +39.4% |
| 2020 | $8.2B | −10.7% |
| 2019 | $9.1B | +8.9% |
| 2018 | $8.4B | −29.4% |
| 2017 | $11.9B | −30.2% |
| 2016 | $17.0B | −19.8% |
| 2015 | $21.3B | +65.8% |
| 2014 | $12.8B | +312.8% |
| 2013 | $3.1B | −2.8% |
| 2012 | $3.2B | −12.2% |
| 2011 | $3.6B | +28.4% |
| 2010 | $2.8B | −8.0% |
| 2009 | $3.1B | +43.7% |
| 2008 | $2.1B | +28.4% |
| 2007 | $1.7B | — |